Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag(Institut Gustave Roussy), Gilles Salles(Memorial Sloan Kettering Cancer Center), Bertrand Coiffier(Unknown), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Steven Le Gouill(Inserm), Catherine Chassagne‐Clément(Centre Léon Bérard), Serge Koscielny(Institut Gustave Roussy), Guillaume Cartron(Hôpital Saint Eloi), Thibaut Leguay(Centre Hospitalier Universitaire de Bordeaux), Thierry Lamy(Centre Hospitalier Universitaire de Lille), Véronique Vergé(Université Paris-Saclay), Clara Mariette(Université Grenoble Alpes), Jérôme Cornillon(Institute Cancer De La Loire Lucien Neuwirth), Franck Morschhauser(Hôpital Claude Huriez), Mario Ojeda‐Uribe, Olivier Casasnovas, Luc-Mathieu Fornecker(Hôpital d'Hautepierre), Stéphane Girault(Centre Hospitalier Universitaire de Limoges), Hervé Ghesquières(Université Claude Bernard Lyon 1), Hervé Dombret(University of London Institute in Paris), Jacques Bosq(Embody (France)), Hervé Tilly(Centre Virchow-Villermé)
Cited by 190
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k